CliffBio
biologic

Besponsa

inotuzumab ozogamicin

Loss of exclusivityAugust 2029projected — 12-year biologic exclusivity estimate
CompanyWyeth →View the full company profile on CliffBio

Drug detail

Brand nameBesponsa
Active ingredientinotuzumab ozogamicin
Strength0.9MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2017
Marketing statusRx

More from Wyeth

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Besponsa patent cliff — loss of exclusivity August 2029 | CliffBio